Biotech firms such as Atara took a heavy hit in its share price following trade tensions between the U.S. and China. The latest round of negotiations with China that knocked billions of dollars of value from tri-county public firms might have been just the signal the market needed to let off a little steam. The…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
